What Can We Expect From Biomarkers for Acute Kidney Injury?

Abstract

Biomarkers for acute kidney injury have numerous potential roles to play both at the bedside and in the design and conduct of clinical trials. Given the heterogeneous nature of this disease and the difficulty, so far, in developing effective therapies, a strategy that deploys all of our available tools in the treatment and in study of treatments would seem prudent. In this review, we discuss how biomarkers will change the way we do we take care of patients with and do clinical trials in acute kidney injury and why, in fact, biomarkers are necessary.

Keywords::

• acute kidney injury
• acute renal failure
• biomarkers
• clinical trial design
• diagnostics
• risk assessment

Financial & competing interests disclosure

JA Kellum has received grants and served as a paid consultant to multiple companies involved in developing biomarkers for acute kidney injury, including Abbott, Alere, Astute and Roche. He has received royalties through the University of Pittsburgh for biomarker technology licensed to Astute Medical. P Devarajan has received royalties through Cincinnati Children’s Hospital for biomarker technology licensed to Abbott and Alere. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

JA Kellum has received grants and served as a paid consultant to multiple companies involved in developing biomarkers for acute kidney injury, including Abbott, Alere, Astute and Roche. He has received royalties through the University of Pittsburgh for biomarker technology licensed to Astute Medical. P Devarajan has received royalties through Cincinnati Children’s Hospital for biomarker technology licensed to Abbott and Alere. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.